Industries > Pharma > Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024

Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024

Opportunities for Leading Companies

PUBLISHED: 15 August 2014
PAGES: 182

WOOCS 2.2.1
SKU: PHA0004 Categories: , ,

Alzheimer’s medicine – your guide to technologies, trends and revenues
Where is the Alzheimer’s disease treatment market heading? Visiongain’s new report gives you revenue predictions for those drugs and diagnostic tests from 2014, helping you stay ahead.

Our 182-page report provides 131 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
– Dr. Simon Ridley, Head of Research, Alzheimer’s Research UK
– David Hanlon, Director of Business Development and Strategic Collaborations, Quanterix
– Elizabeth Edgerly, PhD., Chief Program Officer, The Alzheimer’s Association Northern California and Northern Nevada

Many opportunities exist for diagnosis and treatment of Alzheimer’s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead

Discover sales predictions for the world market and submarkets
Along with revenue prediction of the overall world market, you see forecasts to 2024 for these two submarkets:
• Medicines for Alzheimer’s disease
• Diagnostics for Alzheimer’s (including biomarkers).

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for Alzheimer’s disease drugs
How will leading drugs perform to 2024 at world level? Our study predicts individual revenues of three products:
• Namenda
• Aricept
• Exelon

And also three pipeline products:
• Solanezumab
• Gantenerumab
• MK-8931

There you discover how high sales can go. You see what’s happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2014.

In addition to analyses of the overall world market, you discover revenue forecasts for 11 leading national markets to 2024:
• US
• Japan
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• China
• Brazil
• Russia
• India
• Rest of the World

There you find potential. Large companies and specialty biopharma and diagnostics firms face many opportunities. Our study explains, assessing developments to help your work.

Leading companies and potential for market growth
Overall world revenue for Alzheimer’s disease therapeutics and diagnostics will reach $7.0bn in 2014, our work forecasts. Our new study predicts the market will expand fast, especially beyond 2018. Disease-modifying therapies will transform that market. New drugs hold great potential from 2018 to 2024, given the prevalence of Alzheimer’s and needs for more-effective treatments.

Our work shows you what organisation hold greatest potential. See profiles of 14 leading companies, including these:
• Pfizer
• Eisai
• Forest Laboratories
• Lundbeck
• Daiichi Sankyo
• Novartis
• TauRx Therapeutics
• Transtech Pharma
• Eli Lilly
• Amarantus BioScience Holdings, Inc
• Piramal Enterprises
• GE Healthcare
• Navidea
• Diagenic

In general, a company profile gives you the following information:
• Revenue forecasts for Alzheimer’s disease drugs from 2014 to 2024
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What affects producers of those diagnostic tests and medicines?
Our report discusses issues and events affecting that industry and market from 2014, including these:
• Research and development (R&D) – drugs, diagnostic tests, and related technologies
• Disease prevalence – expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines – changes and opportunities.

The study also discusses other aspects of diagnosing and treating Alzheimer’s:
• Needs for Alzheimer’s treatments
• Drugs and related technologies to transform the market
• Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging
• Diagnostic tests in development
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.

That way, you explore the industry’s strengths, weaknesses, opportunities, and threats. You also analyse it through Porter’s five forces.

See, then, what the future holds.

How the Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024: Opportunities for Leading Companies report helps you
In summary, our 182-page report gives you the following knowledge:
Revenue forecast to 2024 for the world Alzheimer’s disease therapeutics and diagnostics market and 2 submarkets – Discover the industry’s prospects, finding promising places for investment and revenues.
Revenue forecasts to 2024 for the leading 11 national markets – US, Japan, Germany, France, UK, Italy, Spain, Rest of Europe, Brazil, Russia, China, India, and Rest of the World
Assessment of 14 leading companies – hear about products, results and strategies including revenue forecasts for Alzheimer’s disease drugs to 2024
Predicted revenues for 3 Alzheimer’s disease drugs in the market and 3 promising drugs in the pipeline to 2024 – see potentials of top products and promising products in development.
Review of R&D pipelines – investigate developmental trends and progress
Discussion of what stimulates and restrains companies in the market
Prospects for established firms and those seeking to enter the market
View opinions from our survey, seeing interviews with three leading authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Alzheimer’s disease therapeutics and diagnostics market and leading companies. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024

Download sample pages

Complete the form below to download your free sample pages for Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024

Latest Pharma news

Visiongain Publishes Single-Cell Analysis Market Report 2022-2032

The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

26 May 2022


Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022


Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022


Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022